Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.

ABSTRACT:

Background

Basal cell carcinoma (BCC) is the most common cancer type worldwide. Although there are several treatment options for the treatment of BCC, selecting the best treatment option for periorbital BCC is challenging and it varies case by case. More than half of periocular BCC cases initially occur on the inner angle and lower lid. The treatment options for BCC include radical surgical excision using Mohs micrographic technique, radiotherapy, neoadjuvant vismodegib, imiquimod, and combination therapy followed by reconstruction for functionality and aesthetic outcome. Selection of each treatment varies based on the severity and extension of BCC.

Case description

We report a case of periorbital BCC invading the left lower eyelid in a 50-year-old Caucasian male which was i

SUBMITTER: Jabbehdari S 

PROVIDER: S-EPMC11193564 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature